| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -7.9 | -10.1 |
| Net income | -8.0 | -10.1 |
| EPS (diluted, $ a share) | $-0.30 | $-0.60 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: ELTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Elicio Therapeutics, Inc.: key numbers
- Share price
- $1.48Close, Nov 16
- Market cap
- $41.9M
- Shares outstanding
- 28.31MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Elicio Therapeutics, Inc.
All →Elicio Therapeutics Shareholder Meeting
Elicio Therapeutics held its 2026 Annual Meeting of Stockholders on November 12, 2026. Shareholders elected three Class III directors (Julian Adams, Jay R. Venkatesan, and Carol Ashe) to three-year terms and ratified Baker Tilly US, LLP as the company's independent auditor for the fiscal year ending December 31, 2026.
Elicio Therapeutics Financial Results
Elicio Therapeutics reported financial results for the third quarter ended September 30, 2026, and provided updates on its camupepimut clinical program. The company highlighted Phase 2 AMPLIFY-7P data in pancreatic cancer showing a 49% reduction in risk of recurrence or death in ctDNA-negative patients, which will inform its Phase 3 strategy.
“We are excited by the new Phase 2 AMPLIFY-7P findings in adjuvant PDAC, which provide encouraging direction and important insights as we advance camupepimut toward late-stage development and refine our Phase 3 strategy in adjuvant PDAC.”
Robert Connelly, President and Chief Executive Officer
“The 49% lower risk of disease recurrence or death among patients with undetectable ctDNA at baseline, alongside a 43% reduction in risk among ctDNA-positive patients, reinforces the encouraging clinical activity observed across both subgroups.”
Robert Connelly, President and Chief Executive Officer
Elicio Therapeutics Shareholder Meeting
Elicio Therapeutics has scheduled its 2026 Annual Meeting of Stockholders for November 12, 2026. Because the meeting date has shifted by more than 30 days from the prior year's anniversary, the company established September 24, 2026, as the new deadline for shareholder proposals and director nominations.